{"prompt": "['LIST OF ABBREVIATIONS', '5-HT2A', '5-Hydroxytryptomine 2A Receptor', 'AE', 'Adverse Event', 'AIMS', 'Abnormal Involuntary Movement Scale', 'ALT', 'Alanine Aminotransferase', 'ANCOVA', 'Analysis of Covariance', 'ARH', 'Heterogeneous Autoregressive', 'AST', 'Aspartate Aminotransferase', 'BARS', 'Barnes Akathisia Rating Scale', 'BLQ', 'Below the limit of quantification', 'BMI', 'Body Mass Index', 'CFR', 'Code of Federal Regulations', 'CGI-BP', 'Clinical Global Impression Scale, Bipolar version', 'CGI-BP-S', 'Clinical Global Impression Scale, Bipolar version, Severity', 'CI', 'Confidence Interval', 'CRF', 'Case Report Form', 'CRO', 'Contract Research Organization', 'CS', 'Compound Symmetry', 'CSH', 'Heterogeneous Compound Symmetry', 'C-SSRS', 'Columbia Suicide Severity Rating Scale', 'D2', 'Dopamine 2 Receptor', 'DSM-5', 'Diagnostic and Statistical Manual, 5th Edition', 'eCRF', 'Electronic Case Report Form', 'ECG', 'Electrocardiogram', 'ENR', 'All Patients Enrolled', 'FDA', 'Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'HbA1c', 'Glycated Hemoglobin A1c', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HIV', 'Human Immunodeficiency Virus', 'IB', \"Investigator's Brochure\", 'ICF', 'Informed Consent Form', 'ICH', 'International Conference on Harmonisation', 'IEC', 'Independent Ethics Committee', 'Intra-Cellular Therapies, Inc. Confidential', 'viii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['IND', 'Investigational New Drug Application', 'IRB', 'Institutional Review Board', 'ITI', 'Intra-Cellular Therapies, Inc.', 'ITT', 'Intent to Treat', 'IVRS', 'Interactive Voice Response System', 'IWRS', 'Interactive Web Response System', 'LDL', 'Low-density Lipoprotein', 'LOCF', 'Last Observation Carried Over', 'LSM', 'Least-squares mean', 'MADRS', 'Montgomery-Asberg Depression Rating Scale', 'MDE', 'Major Depressive Episode', 'MedDRA\u00ae', 'Medical Dictionary for Regulatory Activities', 'MINI', 'Mini International Neuropsychiatric Interview (M.I.N.I.)', 'MMRM', 'Mixed Model for Repeated Measures', 'NDA', 'New Drug Application', 'OHRP', 'Office for Human Research Protections', 'PET', 'Positron Emission Tomography', 'PI', 'Principal Investigator', 'PK', 'Pharmacokinetic', 'PP', 'Per Protocol', 'QA', 'Quality Assurance', 'QC', 'Quality Control', 'Q-LES-Q-SF', 'Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form', 'QTcB', 'Corrected QT Interval Using the Bazett Formula', 'QTcF', 'Corrected QT Interval Using the Fridericia Formula', 'RND', 'All Patients Randomized', 'SAE', 'Serious Adverse Event', 'SERT', 'Serotonin Transporter', 'SAP', 'Statistical Analysis Plan', 'SAS', 'Simpson Angus Scale', 'SOP', 'Standard Operating Procedure', 'TEAE', 'Treatment emergent adverse event', 'TOEP', 'Toeplitz Structure', 'TOEPH', 'Heterogeneous Toeplitz Structure', 'ULN', 'Upper Limit of Normal', 'Intra-Cellular Therapies, Inc. Confidential', 'ix ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['UP', 'Unanticipated Problem', 'US', 'United States', 'YMRS', 'Young Mania Rating Scale', 'Intra-Cellular Therapies, Inc. Confidential', 'X ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}